Program
Human Growth Hormone
Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.
Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 340 open or running | phase 4since Sep 13, 2005 | Feb 1, 2005 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 194 open or running | phase 4since Nov 27, 2014 | Apr 21, 2011 | Apr 28, 2027phase 4 · NCT07691125 |
| Merck KGaA, Darmstadt, Germanyits history only | 190 open or running | phase 4since Nov 18, 2005 | May 13, 2004 | none ahead |
| Pfizer | 180 open or running | phase 4since Feb 5, 2007 | Sep 9, 2005 | none ahead |
| Eli Lillyits history only | 100 open or running | phase 4since Dec 15, 2005 | Sep 12, 2005 | none ahead |
| LG Chemits history only | 40 open or running | phase 4since Nov 10, 2016 | Dec 29, 2005 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Jan 19, 2016 | Sep 23, 2011 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Dec 4, 2014 | Mar 11, 2004 | none ahead |
| Ipsenits history only | 20 open or running | phase 4since Aug 24, 2011 | Oct 5, 2005 | none ahead |
| Altus Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 28, 2011 | Nov 28, 2011 | none ahead |
| Clinique Ovoits history only | 10 open or running | phase 4since Oct 24, 2012 | Oct 24, 2012 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Mar 23, 2007 | Mar 23, 2007 | none ahead |
| Zhongshan Sansure Hygene Biomedicineits history only | 11 open or running | phase 3since Sep 2, 2026 | Sep 2, 2026 | Oct 2028phase 3 · NCT07815626 |
Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 9, 2005First studies: 7 phase 3 studiesFirst studyNCT00174291, NCT00174278, NCT00174252 and 4 more
- Sep 12, 2005Phase 2 study in Growth Hormone TherapyNCT00174460 · 33 enrolled · Germany
- Nov 2, 2006Phase 3 study in Idiopathic Short StatureNCT00396097 · 316 enrolled · United States
- Feb 5, 2007Phase 4 study in Brain InjuriesNCT00432263
- Oct 24, 2007Phase 4 study in Brain InjuriesNCT00555009 · 10 enrolled · France, Italy, Netherlands and more
- Feb 19, 20083 phase 3 studiesNCT00625872, NCT00627523, NCT00630487
- Feb 22, 2010Phase 3 study in Growth DisordersNCT01073605 · 208 enrolled · France
- Apr 17, 2013Phase 4 study in DwarfismNCT01859949 · 62 enrolled · Japan
- Dec 21, 2018Phase 3 study in Dwarfism, PituitaryNCT03831880 · 87 enrolled · United States, Bulgaria, Czechia and more
- Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125
- Apr 14, 2026Phase 1 study in HealthyNCT07542886 · 27 enrolled · Belgium
TargetBeta
“Growth hormone receptor agonist”ChEMBL 37, by rule
Other programs on GHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lonapegsomatropinrule | ascendis-pharma-endocrinology-division-a-s | phase 3 | 6 |
Studies
All 18 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07542886Healthy · Belgium | 1 | Completed | Jun 25, 2026 | 27 |
| NCT03831880Dwarfism, Pituitary · United States, Bulgaria, Czechia and more | 3 | Completed | Aug 28, 2020 | 87 |
| NCT01859949Dwarfism · Japan | 4 | Completed | Aug 2015 | 62 |
| NCT01073605Growth Disorders · France | 3 | Completed | May 2009 | 208 |
| NCT00630487Dwarfism, Pituitary · Germany | 3 | Terminated | Oct 2008 | 9 |
| NCT00627523Infant, Small for Gestational Age · Belgium, Czech Republic, France and more | 3 | Completed | Dec 2013 | 43 |
| NCT00625872Growth Hormone Therapy · Germany | 3 | Terminated | Mar 2011 | 23 |
| NCT00555009Brain Injuries · France, Italy, Netherlands and more | 4 | Terminated | Jan 2009 | 10 |
| NCT00432263Brain Injuries | 4 | Withdrawn | 0 | |
| NCT00396097Idiopathic Short Stature · United States | 3 | Completed | Aug 2012 | 316 |
| NCT00174460Growth Hormone Therapy · Germany | 2 | Completed | Mar 2008 | 33 |
| NCT00174408Growth Disorders | 3 | Completed | 110 | |
| NCT00174291Endocrine System Diseases · France | 3 | Terminated | Oct 2011 | 21 |
| NCT00174278Dwarfism, Pituitary · France | 3 | Completed | 14 | |
| NCT00174252Fetal Growth Retardation · France | 3 | Completed | Apr 2009 | 57 |
| NCT00174187Endocrine System Diseases · France | 3 | Terminated | Sep 2011 | 30 |
| NCT00163215Endocrine System Diseases · France | 3 | Completed | Oct 2011 | 46 |
| NCT00163189Dwarfism, Pituitary · France | 3 | Completed | Dec 2014 | 98 |
How it is read
Names in the registry
- “somatropin”, 52 entries
- “Somatropin”, 27 entries
- “PEG-somatropin”, 13 entries
- “Saizen®”, 6 entries
- “Genotropin”, 5 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 38 studies
- Turner Syndrome, 10 studies
- Dwarfism, 6 studies
- Growth Disorders, 4 studies
- Genetic Diseases, Inborn, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.